

JOHAN ASKLING PUBLICATIONS 2011**Peer reviewed articles**

75. Söderlund S, Tribukait B, Öst Å, Broström O, Karlén P, Löfberg R, **Askling J**, Sjöqvist U. Colitis-associated DNA aneuploidy and dysplasia in Crohn's disease and risk of colorectal cancer. *Inflamm Bowel Dis*. 2011 May;17(5):1101-7. PMID: 20853434.
76. Strangfeld A, Hyrich K, **Askling J**, Arkema E, Davies R, Listing J, Neovius M, Simard J, Symmons D, Watson K, Zink A. Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. *Rheumatology (Oxford)*. 2011 Jan;50(1):146-51. PMID: 20861148.
77. Saevarsdottir S, Wedrén S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, **Askling J**, Alfredsson L, Klareskog L. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. *Arthritis Rheum*. 2011 Jan;63(1):26-36. PMID: 20862678
78. Knight A, Sandin S, **Askling J**. Increased risk of autoimmune disease in families with Wegener's granulomatosis. *J Rheumatol*. 2010 Dec;37(12):2553-8. PMID: 20889595.
79. Neovius M, Sundström A, Simard J, Wettermark B, Cars T, Feltelius N, **Askling J**, Klareskog L; ARTIS Study Group. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. *Scand J Rheumatol*. 2011 Jan;40(1):8-15. PMID: 20955087.
80. Neovius M, Simard J, Sundström A, Jacobsson L, Geborek P, Saxne T, Feltelius N, Klareskog L, **Askling J**; ARTIS Study Group. Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register. *Ann Rheum Dis*. 2011 Mar;70(3):516-9. PMID: 21081525.
81. Simard JF, Arkema EV, Sundström A, Geborek P, Saxne T, Baecklund E, Coster L, Dackhammar C, Jacobsson L, Feltelius N, Lindblad S, Rantapää-Dahlqvist S, Klareskog L, van Vollenhoven RF, Neovius M, **Askling J**. Ten years with biologics: to whom do data on effectiveness and safety apply? *Rheumatology (Oxford)*. 2011 Jan;50(1):204-13. PMID: 21084326.
82. Neovius M, Simard JF, **Askling J**; ARTIS study group. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. *Ann Rheum Dis*. 2011 Apr;70(4):624-9. PMID: 21149495.
83. **Askling J**, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. *Pharmacoepidemiol Drug Saf*. 2011 Feb;20(2):119-30. PMID: 21254282.

84. Ludvigsson JF, James S, **Askling J**, Stenestrand U, Ingelsson E. Nationwide cohort study of risk of ischemic heart disease in patients with celiac disease. *Circulation*. 2011 Feb 8;123(5):483-90. PMID: 21262996.
85. Elfström P, Granath F, Ekström Smedby K, Montgomery SM, **Askling J**, Ekbom A, Ludvigsson JF. Risk of lymphoproliferative malignancy in relation to small intestinal histopathology among patients with celiac disease. *J Natl Cancer Inst*. 2011 Mar 2;103(5):436-44. PMID: 21289299.
86. Raaschou P, Simard JF, Neovius M, **Askling J**; Anti-Rheumatic Therapy in Sweden Study Group. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. *Arthritis Rheum*. 2011 Jul;63(7):1812-22. PMID: 21305513.
87. Baecklund E, Backlin C, Mansouri M, Klareskog L, **Askling J**, Iliadou AN, Enblad G, Lossos IS, Natkunam Y, Rosenquist R. LMO2 protein expression predicts survival in patients with rheumatoid arthritis and diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2011 Jun;52(6):1146-9. PMID: 21375434.
88. Neovius M, Simard JF, **Askling J**; ARTIS Study Group. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? *Ann Rheum Dis*. 2011 Jun;70(6):1010-5. PMID: 21406455.
89. Neovius M, Simard JF, Klareskog L, **Askling J**; ARTIS Study Group. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. *Ann Rheum Dis*. 2011 Aug;70(8):1407-14. Epub 2011 Apr 25. PMID: 21518724.
90. Olén O, **Askling J**, Ludvigsson JF, Hildebrand H, Ekbom A, Smedby KE. Coeliac disease characteristics, compliance to a gluten free diet and risk of lymphoma by subtype. *Dig Liver Dis*. 2011 Nov;43(11):862-8. PMID: 21880561.
92. Elmberg M, Hultcrantz R, Simard JF, Stål P, Pehrsson K, **Askling J**. Risk of ischaemic heart disease and cardiomyopathy in patients with haemochromatosis and in their first-degree relatives: a nationwide, population-based study. *J Intern Med*. 2011 Oct 25. PMID: 22026548.
93. Simard J, Neovius M, **Askling J**, on behalf of the ARTIS study group. Drug-specific mortality following treatment of RA with TNF-inhibitors. *Arthritis & Rheumatism*, provisional acceptance
94. Holmqvist M, Wallberg S, Jacobsson L, **Askling J**. Rheumatoid arthritis and risk of ischemic and hemorrhagic stroke – a nationwide population-based study. *Annals of the Rheumatic Diseases*, accepted for publication
95. Bombardier C, Hazlewood G, Akhavan P, Schieir O, Dooley A, Haraoui B, Khraishi M, LeClercq S, Légaré S, Mosher D, Pencharz J, Pope J, Thomson J, Thorne C, Zimmer M, Gardam M, **Askling J**, Bykerk V. Canadian Rheumatology Association (CRA) Recommendations for the Pharmacological Management of Rheumatoid Arthritis with

Traditional and Biologic Disease Modifying Anti-Rheumatic Drugs: Part II Safety, Rheumatology, accepted for publication